Pharmaceutical Industry discussion, review, analysis, news and information.

Previously, in April 2004, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Solvay Pharmaceutical B.V. have previously entered into co-development and co-commercialization agreements for bifeprunox and other neuroscience compounds.

The said old collaboration has already resulted to a New Drug Application (NDA) submitted on October 11, 2006 to the USFDA for bifeprunox for the treatment schizophrenic patients while development continues on two other clinical stage neuroscience projects (SLV-313 and SLV-314, which were part of the 2004 agreements).

Now, the two companies have entered into a new neuroscience discovery, co-development, and co-commercialization agreement.

Under the new agreement, the parties will collaborate in a joint discovery effort targeting the identification of small molecules as potential anti-psychotic medications.

Any compounds discovered as part of the research collaboration will be jointly co-owned and patented by Wyeth and Solvay as well as co-developed and co-commercialized by the two companies.